A master regulator of cholesterol biosynthesis constitutes a therapeutic liability of triple negative breast cancer
Lipid and cholesterol reprogramming are often observed in specific cancer subtypes. We find that triple-negative breast cancers (TNBCs), but not estrogen receptor-positive (ER+) ones, adopt nuclear receptor RAR-related orphan receptor γ (RORγ) as their new master activator of cholesterol biosynthesi...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2020-03-01
|
| Series: | Molecular & Cellular Oncology |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/23723556.2019.1701362 |
| _version_ | 1827809371839528960 |
|---|---|
| author | Demin Cai Xiong Zhang Hong-Wu Chen |
| author_facet | Demin Cai Xiong Zhang Hong-Wu Chen |
| author_sort | Demin Cai |
| collection | DOAJ |
| description | Lipid and cholesterol reprogramming are often observed in specific cancer subtypes. We find that triple-negative breast cancers (TNBCs), but not estrogen receptor-positive (ER+) ones, adopt nuclear receptor RAR-related orphan receptor γ (RORγ) as their new master activator of cholesterol biosynthesis program. Its dominant role over sterol regulatory element-binding protein 2 (SREBP2) renders TNBC highly vulnerable to RORγ inhibitors alone or in combination with statins. |
| first_indexed | 2024-03-11T22:41:14Z |
| format | Article |
| id | doaj.art-d959a8d3aa7c4195a83989e8a3c57144 |
| institution | Directory Open Access Journal |
| issn | 2372-3556 |
| language | English |
| last_indexed | 2024-03-11T22:41:14Z |
| publishDate | 2020-03-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Molecular & Cellular Oncology |
| spelling | doaj.art-d959a8d3aa7c4195a83989e8a3c571442023-09-22T09:11:01ZengTaylor & Francis GroupMolecular & Cellular Oncology2372-35562020-03-017210.1080/23723556.2019.17013621701362A master regulator of cholesterol biosynthesis constitutes a therapeutic liability of triple negative breast cancerDemin Cai0Xiong Zhang1Hong-Wu Chen2University of California DavisUniversity of California DavisUniversity of California DavisLipid and cholesterol reprogramming are often observed in specific cancer subtypes. We find that triple-negative breast cancers (TNBCs), but not estrogen receptor-positive (ER+) ones, adopt nuclear receptor RAR-related orphan receptor γ (RORγ) as their new master activator of cholesterol biosynthesis program. Its dominant role over sterol regulatory element-binding protein 2 (SREBP2) renders TNBC highly vulnerable to RORγ inhibitors alone or in combination with statins.http://dx.doi.org/10.1080/23723556.2019.1701362tnbccholesterol homeostasisstatinser-positive breast cancerrorγsrebp2chromatintherapy |
| spellingShingle | Demin Cai Xiong Zhang Hong-Wu Chen A master regulator of cholesterol biosynthesis constitutes a therapeutic liability of triple negative breast cancer Molecular & Cellular Oncology tnbc cholesterol homeostasis statins er-positive breast cancer rorγ srebp2 chromatin therapy |
| title | A master regulator of cholesterol biosynthesis constitutes a therapeutic liability of triple negative breast cancer |
| title_full | A master regulator of cholesterol biosynthesis constitutes a therapeutic liability of triple negative breast cancer |
| title_fullStr | A master regulator of cholesterol biosynthesis constitutes a therapeutic liability of triple negative breast cancer |
| title_full_unstemmed | A master regulator of cholesterol biosynthesis constitutes a therapeutic liability of triple negative breast cancer |
| title_short | A master regulator of cholesterol biosynthesis constitutes a therapeutic liability of triple negative breast cancer |
| title_sort | master regulator of cholesterol biosynthesis constitutes a therapeutic liability of triple negative breast cancer |
| topic | tnbc cholesterol homeostasis statins er-positive breast cancer rorγ srebp2 chromatin therapy |
| url | http://dx.doi.org/10.1080/23723556.2019.1701362 |
| work_keys_str_mv | AT demincai amasterregulatorofcholesterolbiosynthesisconstitutesatherapeuticliabilityoftriplenegativebreastcancer AT xiongzhang amasterregulatorofcholesterolbiosynthesisconstitutesatherapeuticliabilityoftriplenegativebreastcancer AT hongwuchen amasterregulatorofcholesterolbiosynthesisconstitutesatherapeuticliabilityoftriplenegativebreastcancer AT demincai masterregulatorofcholesterolbiosynthesisconstitutesatherapeuticliabilityoftriplenegativebreastcancer AT xiongzhang masterregulatorofcholesterolbiosynthesisconstitutesatherapeuticliabilityoftriplenegativebreastcancer AT hongwuchen masterregulatorofcholesterolbiosynthesisconstitutesatherapeuticliabilityoftriplenegativebreastcancer |